US EditionNovartis to acquire Avidity Biosciences for about $12 billion
Novartis will pay a 46% premium to acquire Avidity, enhancing its RNA therapeutics pipeline with late-stage neuromuscular disease candidates and targeting 6% sales CAGR by 2029.
- On October 26, 2025, Novartis AG agreed to acquire Avidity Biosciences, valuing the company at $12 billion and offering a 46% premium to its recent closing price.
- Novartis has pursued deals this year to shore up its pipeline amid a looming patent cliff, with Avidity's AOC platform aligning with Novartis' neuroscience strategy and boosting RNA-targeting delivery.
- Avidity will spin off its early-stage precision cardiology programs into SpinCo before closing, led by Kathleen Gallagher, Chief Program Officer of Avidity, with Sarah Boyce, Avidity Chief Executive Officer, as chair.
- The companies say closing depends on regulatory clearances and shareholder approval, with timing uncertain; Avidity shareholders will receive one SpinCo share per 10 Avidity shares or a pro rata cash distribution, with proxy materials sent before the special meeting.
- Avidity's late-stage programs including del-zota, del-desiran and del-brax aim for near-term regulatory submissions and trial readouts, with key results anticipated next year.
119 Articles
119 Articles
The Basel-based pharmaceutical company Avidity Biosciences wants to take over for 12 billion dollars and promises to boost growth. But the specialized medicines of the Californian company are still not on the market.
The US company is developing novel RNA therapies for the treatment of severe genetic neuromuscular diseases.
Switzerland's Novartis buying San Diego biotech Avidity in $12 billion cash deal
Novartis staff celebrate the company’s 25 years in San Diego outside the Genomics Institute of the Novartis Research Foundation in Torrey Pines. (Photo courtesy of the company) Swiss pharmaceutical giant Novartis announced Sunday that it will buy San Diego-based Avidity Biosciences in a $12 billion all-cash deal. Founded in 2012, Avidity is developing a new class of RNA therapeutics called antibody oligonucleotide conjugates to treat genetic neu…
The agreement should be concluded in the first half of 2026 and followed by the separation of the early Avidity cardiology programmes into a new company.
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
